Cover Image
市場調查報告書

65 kDa磷蛋白:開發中產品分析

65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365794
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
65 kDa磷蛋白:開發中產品分析 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 52 Pages
簡介

本報告提供以65 kDa磷蛋白 為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

65 kDa磷蛋白 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Astellas Pharma Inc.
  • Atara Biotherapeutics, Inc.
  • Immunomic Therapeutics, Inc.
  • Vakzine Projekt Management GmbH
  • Vical Incorporated

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0311TDB

Summary

Global Markets Direct's, '65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Pipeline Review, H1 2016', provides in depth analysis on 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted pipeline therapeutics.

The report provides comprehensive information on the 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus)
  • The report reviews 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted therapeutics and enlists all their major and minor projects
  • The report assesses 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) Overview
  • Therapeutics Development
    • 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Products under Development by Stage of Development
    • 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Products under Development by Therapy Area
    • 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Products under Development by Indication
  • 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Products under Development by Companies
  • 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Products under Development by Universities/Institutes
  • 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc.
    • Atara Biotherapeutics, Inc.
    • Immunomic Therapeutics, Inc.
    • Vakzine Projekt Management GmbH
    • Vical Incorporated
  • 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Drug Profiles
    • Anti-IL-2R Monoclonal Antibody + LAMP-pp65 Dendritic Cell Vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-0113 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target PP65 for Cytomegalovirus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CyMVectin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cytomegalovirus vaccine 1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pp65 DC + Td - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPM-2001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Dormant Projects
  • 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Discontinued Products
  • 65 kDa Phosphoprotein (PP65 or Tegument Protein UL83, Cytomegalovirus) - Featured News & Press Releases
    • Dec 06, 2015: Atara Bio Announces Positive Results From a Phase 2 Clinical Trial of Cytomegalovirus Targeted Cytotoxic T Lymphocytes, a Novel Approach to Adoptive Immunotherapy, to Treat Patients With Refractory CMV Disease in the Central Nervous System
    • Nov 05, 2015: Atara Bio to Present Data on CMV-CTL at the American Society of Hematology Annual Meeting 2015
    • May 21, 2015: Vical Announces Completion of Enrollment in Phase 2 Clinical Trial of Investigational CMV Vaccine in Kidney Transplant Recipients
    • Apr 21, 2015: Vical Announces Presentation of Preclinical Data for Congenital CMV DNA Vaccine at International Conference
    • Dec 10, 2013: Astellas and Vical Announce Initiation of Phase 2 Trial of ASP0113, a Cytomegalovirus Vaccine, in Solid Organ Transplant Recipients
    • Jun 25, 2013: Vical And Astellas Initiate Phase III Trial Of ASP0113 Cytomegalovirus Vaccine
    • Apr 02, 2012: Astellas And Vical Advance Toward Phase III Trial Of TransVax CMV Vaccine Triggering $10m Milestone Payment To Vical
    • Jan 11, 2012: Vical Provides Update On CyMVectin Prophylactic Vaccine
    • Jan 11, 2012: Vical Announces Online Publication Of Phase II Proof-Of-Concept Trial Results Of TransVax
    • Jul 14, 2011: Vical Announces Scientific Advances On CyMVectin At DNA Vaccines 2011 Conference
    • Jul 14, 2011: Vical Announces Scientific Advances For TransVax At DNA Vaccines 2011 Conference
    • May 19, 2011: Vical To Present TransVax And DNA Vaccines At ASGCT Conference
    • Apr 14, 2011: Vical Receives Key European Patent For TransVax Cytomegalovirus Vaccine
    • Mar 02, 2011: Vical Receives Positive Scientific Advice From EMA For TransVax Phase III Trial
    • Sep 13, 2010: Vical Announces Positive Results From Phase II Trial Of TransVax CMV Vaccine
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Astellas Pharma Inc., H1 2016
  • Pipeline by Atara Biotherapeutics, Inc., H1 2016
  • Pipeline by Immunomic Therapeutics, Inc., H1 2016
  • Pipeline by Vakzine Projekt Management GmbH, H1 2016
  • Pipeline by Vical Incorporated, H1 2016
  • Dormant Projects, H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top